This study tests a new medicine called PMN310 in people with early Alzheimer's disease. The goal is to see if it is safe and how it affects Alzheimer's-related changes in the body. About 144 volunteers will receive multiple doses of the drug or a placebo. This is an early-phase t…
Phase: PHASE1 • Sponsor: ProMis Neurosciences, Inc • Aim: Disease control
Last updated May 11, 2026 20:47 UTC